Opinion|Videos|November 18, 2024

Current Treatment Landscape of AQP4-IgG+ NMOSD and Considerations on Relapse Rates

Michael Levy, MD, PhD, discusses how Aquaporin-4 IgG-seropositive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD) is a rare autoimmune condition affecting the central nervous system. Anti-CD20 therapies, particularly rituximab, have led to increased relapse rates.

Video content above is prompted by the following:
  1. Briefly review the current treatment landscape for aquaporin-4 IgG–seropositive (AQP4-IgG+) NMOSD and the role of anti-CD20 therapies, particularly rituximab.
  2. Could you speak to the clinical significance of these findings and their implications for the neurology community?
  3. How do these data compare to what you see in your clinical practice?

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Latest CME